Walk into a large health system’s pharmacy, and you’ll see procurement infrastructure most independent practices can only dream about. Group purchasing organization contracts that negotiate allocation priority. Dedicated formulary committees meeting weekly. Pharmacy informatics teams monitoring shortage databases in real time. Inventory management software that tracks every vial across dozens of service lines. That infrastructure costs millions of dollars annually to maintain, and it’s a significant reason why large hospitals manage specialty injectable supply more smoothly than small facilities do.

Meanwhile, the independent infusion centre down the street, the single-specialty rheumatology practice across town, and the ambulatory surgery centre on the next block are trying to source the same $8,000-per-dose biologics and $500-per-vial specialty antibiotics without any of that infrastructure. They’re competing for allocation against systems with ten times their purchasing volume, often through the same distributors, and with none of the dedicated staff whose full-time job is to manage that procurement complexity.

So how do small facilities actually source specialty injectables without hospital-level budgets? It turns out there are practical approaches that work, though they require being strategic about where to invest limited resources and which shortcuts to avoid.

The group purchasing organisation reality for small practices

The first conversation most small facility administrators have when specialty drug costs become painful is about joining a GPO. GPOs negotiate pricing and allocation terms across their membership, theoretically giving smaller members the leverage of a larger buying group. In practice, the benefit for small facilities is real but uneven. GPO contract pricing for specialty injectables is typically better than single-facility direct negotiation, but allocation priority during shortages still favours high-volume members. A 200-bed hospital in a GPO gets preferential allocation over a three-physician infusion centre in the same GPO when manufacturers ration supply.

Association-based purchasing cooperatives offer a complementary path. The National Home Infusion Association (NHIA) and similar specialty-focused organisations have pooled purchasing agreements specifically designed for smaller members. These arrangements often provide better allocation access than large general GPOs because the membership is more homogeneous and the cooperatives negotiate from a specialty-specific position of strength. For small ambulatory infusion centres, specialty pharmacies, and outpatient practices, association purchasing often produces better outcomes than trying to compete inside a large GPO dominated by hospital systems.

Biosimilar adoption is a budget strategy, not just a clinical one

For specialty injectable categories where biosimilars exist (rituximab, trastuzumab, epoetin, filgrastim, infliximab, adalimumab), biosimilar adoption is one of the most significant procurement levers available to small facilities. Per-dose cost savings typically run 15 to 40 percent compared to reference biologics, which compounds meaningfully over a year of therapy for patients on chronic specialty drug regimens.

But the budget benefit is only half the story. Biosimilar adoption also improves supply resilience. The ASHP drug shortage database has repeatedly shown that facilities with active purchasing relationships across multiple biosimilar manufacturers maintain allocation access during shortages that leave single-source buyers scrambling. For a small facility, that dual benefit (lower costs plus better shortage resilience) makes biosimilar adoption arguably more important than it is for a large hospital system with deeper reserves to weather supply disruptions.

Inventory strategy: Where small facilities can outperform large systems

Here’s an underappreciated advantage small facilities have: they can make inventory decisions faster and more nimbly than large hospital systems. A small infusion centre can pivot to a biosimilar alternative in a week if their clinical team agrees. A large hospital system might take six months of formulary committee review to approve the same change. That agility, used strategically, helps offset the budget and infrastructure gap.

For the highest-risk specialty injectable categories in a small facility’s mix (oncology agents, IVIG, specialty antibiotics like imipenem and vancomycin), maintaining 30 to 60 days of inventory when storage and cash flow allow is risk-adjusted procurement, not hoarding. For lower-risk products with multiple stable manufacturers, lean just-in-time ordering is appropriate. The mistake small facilities often make is treating all specialty injectables with the same stocking approach, either overstocking everything and tying up cash flow, or running lean on everything and getting caught by predictable shortages.

Vendor diversification without adding overhead

Hospital pharmacies typically maintain qualified vendor relationships with five to ten specialty drug suppliers. Small facilities often can’t manage that many relationships effectively given staff limits. But two or three qualified vendors is achievable, and it’s enough to meaningfully reduce single-source risk. The key is establishing purchase history with the secondary and tertiary vendors before a shortage hits. Small orders placed consistently across multiple vendors build the allocation history that protects supply access when markets tighten.

Drug Supply Chain Security Act compliance is non-negotiable with every vendor, regardless of facility size. DSCSA requires electronic, serialised traceability for every prescription injectable, with fines reaching $500,000 per violation. Small facilities are particularly vulnerable here because they’re more likely to try unfamiliar vendors during shortages without full compliance verification. Diversified prescription injectable sourcing from DSCSA-compliant vendors protects both operational continuity and legal exposure. Cutting that corner during a shortage to cover patient care is exactly the scenario that leads to compliance findings.

What small facilities should avoid

A few common small-facility strategies sound appealing but underperform. Waiting for the primary supplier to confirm backorder before establishing alternative relationships. Assuming wholesaler allocation will cover small-facility needs without proactive relationship management. Defaulting to single-source purchasing because it simplifies operations, without recognizing that simplification concentrates risk. And treating specialty drug procurement as a clinical-operations afterthought rather than a core business function deserving dedicated attention.

Small facilities don’t need hospital-level budgets to manage specialty injectable procurement well. They need intentional procurement strategy applied consistently over time. Association purchasing, biosimilar adoption, risk-adjusted inventory, vendor diversification, and DSCSA compliance aren’t expensive to implement. What they require is treating specialty drug supply as the patient care infrastructure it actually is, rather than a line-item procurement exercise that gets attention only when something breaks.

USA MedPremium, a B2B medical supply company serving healthcare facilities nationwide from Fort Lauderdale, Florida.